About UroToday® - GU OncToday™

About UroToday® - GU OncToday

UroToday - GU OncToday publishes evidence-based clinical content that is organized across the site by disease, treatments and guidelines.  This educational platform offers written articles, video lectures, discussions blogs.  The content ranges from emerging data presented at conferences, consensus meetings, clinical practice cases, highlights on publications and GU oncology clinical trials while actively recruiting. The content across the site is developed, organized and presented by leaders across the urology and oncology fields.  The Centers of Excellence (CoE) provide state of the art lectures, original articles, discussions videos and research findings organized by diseases and conditions and focused on what is known about treatments or what is emerging in clinical care. Each CoE is led by a clinician-editor and contribtions from invited faculty.  

Mission
Since 2003 UroToday’s mission is to provide free, accurate, timely, evidence-based urological and oncological content to support healthcare providers in their need to stay up-to-date on diseases and conditions and to assist both clinicians and patients in improved understanding of diagnosis and treatment -- Empowering both groups to access evidence-based practice from anywhere in the world to advance the art and science of urology. 

Management Team
Gina B. Carithers is the Founder and CEO of UroToday, the UroToday International Journal, Everyday Urology - Oncology Insights, and recently GU OncToday all Digital Science Press publications. UroToday was launched in 2003 to establish an up-to-date, accessible, clinical reference platform that reinvented the traditional ways of disseminating genitourinary disease and condition information. UroToday offers content in text (250 content items posted each week), state of the art peer-to-peer lectures, clinical paper commentaries by the authors (Beyond the Abstracts), coverage of international conferences and a listing of GU Oncology clinical trials that are actively recruiting.  With over 20 years at DuPont Pharmaceuticals, Ms. Carithers acquired a diversified experience in the  commercialization strategies of pharmaceuticals.  She learned that education is the best and only strategy needed for marketing therapies that seek to meet unmet medical needs for serious and life-threatening conditions. It was in 1998 while working with a team on the launch of a then new HIV medication she met a activist who was also a patient and educator.  He was the Founder and Medical Editor for a treatment website for HIV and viral hepatitis. He was dedicated, supportive, humorous, and oh so bright.  This human experience ignited her passion for equal and open access to clinical information.  She drove education and outreach that engaged both the health care professionals and the patients in her later leadership roles at DuPont.  After DuPont Pharmaceuticals was divested she did consulting while looking for her next work chapter.  During this time she consulted for a pharmaceutical company and developed "Urological Masters." During the development of this education program she realized that the content was cost prohibitive and accessing it was time intensive.  The genesis of UroToday was the result.  Today it is the platforms of Digital Science Press  that engages her and provides quality, state of the art access to unbiased information that translates clinical trial data into improving health and patient outcomes in urology. 

Joe Palumbo, President of Digital Science Press, Inc. joined the leadership team in January 2016.  For the past 20 years, Mr. Palumbo's focus has been serving his client's educational needs.  Pharmaceutical, medical device, and biotech companies have trusted his ability to cultivate strong relationships while developing cost-effective, strategic communication solutions. Prior to joining Digital Science Press in his executive role leading business development, Joe spent several years working with publishers, most recently with Elsevier. 

We welcome your feedback and contributions towards continuing to make UroToday and GU OncToday a credible and invaluable resources.
Please feel to contact us: